New Haven Pharmaceuticals gets $1.5M investment; Drug-eluting stents safe and effective;

> Second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions, according to results at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Press release

> Oral controlled release company New Haven Pharmaceuticals has received a $1.5M investment from Connecticut Innovations as part of a $6.6M Series A funding round. Press release

> Drug-eluting balloons are as effective as drug-eluting stents in opening up restenosed arteries. Article

> The U.S. FDA has accepted Ferring Pharmaceuticals' filing of an NDA for its controlled release misoprostol vaginal insert, used in childbirth. Press release

And Finally... Drug-coated stents may have benefits over bare metal stents in patients over 80. Article

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.